4105.TWO
Strong BuyFull HouseAI screen passTTY Biopharm Company Limited · Healthcare · Taiwan · $612M
TWD 80.90 +0.7% · close 8 Oct · scored 10 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Read our full research report on 4105.TWO (Jun 2026), freeAs of 10 Oct 2026, MoatMap's StockRank for TTY Biopharm Company Limited (4105.TWO) is 99/100, ranked against 24,000+ stocks in 35 markets (Quality 80, Value 71, Momentum 66, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
TTY Biopharm maintains a strong franchise across specialty oncology, anti-infectives, and critical care pharmaceuticals in Taiwan and international markets. The company combines disciplined profitability and conservative leverage with a sharp upward revision of more than 20% in forward earnings consensus.
ABOUT TTY BIOPHARM COMPANY LIMITED
Read
TTY Biopharm Company Limited is a Taiwanese biopharmaceutical company dedicated to the R&D, manufacturing, and marketing of innovative drugs, particularly in oncology and critical care. Its competitive moat is built on a focused strategy in high-value therapeutic areas, backed by robust R&D capabilities and a pipeline of novel drug candidates. The company actively pursues global expansion for its specialized pharmaceutical products.
FINANCIAL SUMMARY (TWD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.1B | 5.5B | 5.9B | 6.5B | 8.4% | 6.7B | 7.0B | — | 9.2% |
| EPS (TWD) | 4.40 | 4.54 | 5.83 | 6.27 | 12.5% | 6.96 | 7.36 | 7.39 | 8.6% |
| Shares | 248.7M | 248.7M | 248.7M | 248.6M | -0.0% | 248.6M | — | — | — |
| Debt | 1.9B | 1.9B | 1.8B | 1.2B | -13.1% | 2.1B | — | — | — |
| Equity | 5.7B | 5.9B | 6.8B | 7.2B | 8.6% | — | — | — | — |
| Op CF | 1.2B | 1.1B | 1.3B | 1.8B | 12.5% | 2.0B | — | — | — |
| Inv CF | -133.1M | -2.6M | -243.6M | -367.4M | — | — | — | — | — |
| Fin CF | -1.1B | -816.3M | -1.1B | -1.6B | — | — | — | — | — |
Above its 200-day average and 1% below its 52-week high.
Calmer than 97% of stocks we rank over the past year (14% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4105.TWO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 4105.TWO | TTY Biopharm Company Limited(you) | $612M | 99 | Strong Buy |
| 3705.TW | YungShin Global Holding Corporation | $469M | 98 | Strong Buy |
| 1720.TW | Standard Chemical & Pharmaceutical Co., Ltd. | $347M | 97 | Strong Buy |
| 1707.TW | Grape King Bio Ltd | $405M | 88 | Strong Buy |
| 4114.TWO | Synmosa Biopharma Corporation | $471M | 62 | Hold |
| 6620.TWO | Handa Pharmaceuticals, Inc. | $633M | 54 | Hold |
| 1731.TW | Maywufa Company Ltd. | $87M | 92 | Strong Buy |
| 8432.TWO | TSH Biopharm Corporation Limited | $61M | 100 | Strong Buy |
| 4746.TW | Formosa Laboratories, Inc. | $182M | 69 | Buy |
| 1760.TW | Panion & Bf Biotech Inc. | $145M | 70 | Buy |
Peer medians: ROE 3.5% · P/E 16.1x · Gross margin 43.4%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.